US 12,186,292 B2
Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels
Stephen Kirnon, San Ramon, CA (US); Eric Freedland, Marblehead, MA (US); and Rajagopal V. Sekhar, Missouri City, TX (US)
Assigned to Societe des Produits Nestle S.A., Vevey (CH); and Baylor College of Medicine, Houston, TX (US)
Filed by SOCIÉTÉ DES PRODUITS NESTLÉ S.A., Vevey (CH); and BAYLOR COLLEGE OF MEDICINE, Houston, TX (US)
Filed on Dec. 15, 2022, as Appl. No. 18/082,133.
Application 18/082,133 is a division of application No. 17/175,111, filed on Apr. 7, 2022, granted, now 41,787,352.
Application 17/175,111 is a continuation of application No. 15/577,422, granted, now 10,952,982, issued on Mar. 23, 2021, previously published as PCT/US2016/034078, filed on May 25, 2016.
Claims priority of provisional application 62/167,433, filed on May 28, 2015.
Prior Publication US 2023/0137543 A1, May 4, 2023
Int. Cl. A61K 31/155 (2006.01); A23K 20/142 (2016.01); A23K 50/50 (2016.01); A61K 31/167 (2006.01); A61K 31/198 (2006.01); A61K 31/205 (2006.01); A61K 31/223 (2006.01); A61K 31/27 (2006.01); A61K 31/341 (2006.01); A61K 31/381 (2006.01); A61K 31/683 (2006.01); A61K 38/02 (2006.01); A61K 38/05 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); A61P 21/00 (2006.01); A61P 29/00 (2006.01); A61P 31/18 (2006.01); A61P 39/00 (2006.01); A61P 39/06 (2006.01)
CPC A61K 31/198 (2013.01) [A23K 20/142 (2016.05); A23K 50/50 (2016.05); A61K 31/155 (2013.01); A61K 31/167 (2013.01); A61K 31/205 (2013.01); A61K 31/223 (2013.01); A61K 31/27 (2013.01); A61K 31/341 (2013.01); A61K 31/381 (2013.01); A61K 31/683 (2013.01); A61K 38/02 (2013.01); A61K 38/05 (2013.01); A61K 38/21 (2013.01); A61K 45/06 (2013.01); A61P 21/00 (2018.01); A61P 29/00 (2018.01); A61P 31/18 (2018.01); A61P 39/00 (2018.01); A61P 39/06 (2018.01)] 7 Claims
 
1. A method of neutralizing or mitigating a drug-induced mitochondrial dysfunction or impairment for an individual, the method comprising providing to the individual an effective amount of a composition comprising glycine and N-acetylcysteine, wherein the drug-induced mitochondrial dysfunction or impairment is from.